Sheng-Long Ye

3.4k total citations · 2 hit papers
20 papers, 2.1k citations indexed

About

Sheng-Long Ye is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Sheng-Long Ye has authored 20 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 7 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Sheng-Long Ye's work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Hepatitis B Virus Studies (6 papers) and Cancer Mechanisms and Therapy (4 papers). Sheng-Long Ye is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Hepatitis B Virus Studies (6 papers) and Cancer Mechanisms and Therapy (4 papers). Sheng-Long Ye collaborates with scholars based in China, United States and Japan. Sheng-Long Ye's co-authors include Zhao-You Tang, Lun‐Xiu Qin, Ana I. Robles, Yidong Chen, Xin Wei Wang, Marshonna Forgues, A Peng, Li Y, Richard H. Simon and Ping He and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Radiology.

In The Last Decade

Sheng-Long Ye

20 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

2003 679 citations Lun‐Xiu Qin, Marshonna Forgues et al. Nature Medicine profile →
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

2020 194 citations Masatoshi Kudo, Kwang‐Hyub Han et al. Liver Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheng-Long Ye China	16	985	703	533	498	490	20	2.1k
Zhi-Quan Wu China	20	974 1.0×	535 0.8×	436 0.8×	543 1.1×	434 0.9×	61	1.9k
Jianqiang Cai China	19	1.1k 1.1×	694 1.0×	512 1.0×	817 1.6×	631 1.3×	63	2.5k
Xin‐Da Zhou China	27	1.5k 1.5×	678 1.0×	497 0.9×	541 1.1×	672 1.4×	61	2.5k
D. Voliotis Germany	20	1.4k 1.4×	970 1.4×	451 0.8×	953 1.9×	543 1.1×	48	3.0k
Camilla Pilati France	19	542 0.6×	1.1k 1.6×	617 1.2×	1.1k 2.2×	373 0.8×	32	2.7k
Shao-Chun Chang United States	7	676 0.7×	637 0.9×	349 0.7×	1.2k 2.3×	273 0.6×	7	2.2k
Francesco Galimi Italy	24	738 0.7×	1.1k 1.6×	458 0.9×	1.2k 2.3×	154 0.3×	35	2.5k
John Kauh United States	28	875 0.9×	1.0k 1.5×	353 0.7×	1.4k 2.7×	480 1.0×	106	3.0k
Zhong‐Zhe Lin Taiwan	22	498 0.5×	418 0.6×	332 0.6×	740 1.5×	233 0.5×	65	1.5k
W. Grigioni Italy	24	344 0.3×	636 0.9×	604 1.1×	725 1.5×	320 0.7×	59	2.3k

Countries citing papers authored by Sheng-Long Ye

Since Specialization

Citations

This map shows the geographic impact of Sheng-Long Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng-Long Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng-Long Ye more than expected).

Fields of papers citing papers by Sheng-Long Ye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng-Long Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng-Long Ye. The network helps show where Sheng-Long Ye may publish in the future.

Co-authorship network of co-authors of Sheng-Long Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Sheng-Long Ye. A scholar is included among the top collaborators of Sheng-Long Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng-Long Ye. Sheng-Long Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kudo, Masatoshi, Kwang‐Hyub Han, Sheng-Long Ye, et al.. (2020). A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer. 9(3). 245–260. 194 indexed citations breakdown →

Ye, Sheng-Long, Jiamei Yang, Ping Bie, et al.. (2018). Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer. 18(1). 247–247. 10 indexed citations

Ye, Sheng-Long, Xiaoping Chen, Jiamei Yang, et al.. (2017). Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Tumor Biology. 39(3). 3726131103–3726131103. 11 indexed citations

Marrero, Jorge A., Masatoshi Kudo, Alan P. Venook, et al.. (2016). Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. Journal of Hepatology. 65(6). 1140–1147. 264 indexed citations

Geschwind, Jean-François H., Masatoshi Kudo, Jorge A. Marrero, et al.. (2016). TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 279(2). 630–640. 94 indexed citations

Merkle, Elmar M., Christoph J. Zech, Carlo Bartolozzi, et al.. (2015). Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. European Radiology. 26(3). 674–682. 77 indexed citations

Lu, Ligong, et al.. (2015). Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology. 33(8). 894–900. 101 indexed citations

Han, Kwang‐Hyub, Sheng-Long Ye, Jong Young Choi, et al.. (2011). Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. Oncology. 81(Suppl. 1). 158–164. 98 indexed citations

Bridges, John F. P., Gisselle Gallego, Masatoshi Kudo, et al.. (2011). Identifying and prioritizing strategies for comprehensive liver cancer control in Asia. BMC Health Services Research. 11(1). 298–298. 17 indexed citations

10.

Yeo, Winnie, Pei‐Jer Chen, Junji Furuse, et al.. (2010). Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer. 10(1). 620–620. 4 indexed citations

11.

Chen, Pei‐Jer, Junji Furuse, Kwang‐Hyub Han, et al.. (2010). Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver International. 30(10). 1427–1438. 34 indexed citations

12.

Ye, Sheng-Long, et al.. (2010). Current Approaches to the Treatment of Early Hepatocellular Carcinoma. The Oncologist. 15(S4). 34–41. 45 indexed citations

13.

Zhang, Ti, Hui‐Chuan Sun, Peng Wang, et al.. (2009). Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Letters. 290(2). 204–210. 22 indexed citations

14.

Qiu, Shuang-Jian, Lina Lü, Chunping Qiao, et al.. (2005). Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. Journal of Cancer Research and Clinical Oncology. 131(7). 429–438. 19 indexed citations

15.

Qin, Lun‐Xiu, Marshonna Forgues, Ping He, et al.. (2003). Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Medicine. 9(4). 416–423. 679 indexed citations breakdown →

16.

Zhou, Jian, et al.. (2001). The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 127(9). 559–564. 15 indexed citations

17.

Li, Yan, Zhao-You Tang, Sheng-Long Ye, et al.. (2001). Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World Journal of Gastroenterology. 7(5). 630–630. 300 indexed citations

18.

Wang, Zhong, Shuang-Jian Qiu, Sheng-Long Ye, Zhao-You Tang, & Xiao Xiao. (2001). Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Therapy. 8(10). 751–758. 45 indexed citations

19.

Tang, Zhao–You, Jian Tian, Sheng-Long Ye, et al.. (2001). Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential. World Journal of Gastroenterology. 7(5). 597–597. 33 indexed citations

20.

Qiu, Shuang‐Jian, et al.. (1998). The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 124(5). 253–258. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact